Cronos Group Inc. (TSX: CRON)
Health Care · Pharmaceuticals · CA
CA$4.83
+1.90% today · +31.7% 1Y
Cronos Group Inc. (TSX: CRON) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.26B and employs 610 people.
Over the last twelve months the share price has gained 31.7%, trading between 3.23 and 4.78.
Tweenvest scores Cronos Group Inc. across four factors: quality 54/100, value 38/100, growth 100/100. Its strongest factor is growth.
CRON price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.26B
- Revenue (TTM)
- $179.09M
- P/E
- 18.11
- EPS
- 0.18
- Dividend yield
- —
- Beta (5Y)
- 1.24
- 52-week high
- CA$4.78
- 52-week low
- CA$3.23
- Avg volume (3M)
- —
- Shares outstanding
- 368.41M
- Employees
- 610
- Next earnings
- —
About Cronos Group Inc.
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under its Lord Jones and Happy Dance brands through online sales, traditional retail, and hospitality partner networks. The company also plays a significant role in the cultivation, production, and commercialization of cannabis and cannabis-infused products for both medicinal and adult-use sectors. Its comprehensive product offerings encompass dried cannabis flower, pre-rolled joints, edibles, concentrated forms, and cannabis extracts. These are distributed via wholesale partnerships and direct-to-consumer channels, prominently featuring its wellness platform, PEACE NATURALS, and its adult-use brand, Spinach. Moreover, Cronos Group exports dried cannabis and cannabis oils to international markets including Germany, Israel, and Australia. Established in 2012, the company maintains its corporate headquarters in Toronto, Canada.
- ISIN
- CA22717L1013
- Listed since
- Dec 17, 2014
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,253.00 | +0.49% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.09 | +0.02% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $154.72 | +2.69% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.50 | +1.88% |
Figures last refreshed Aug 18, 2026.